These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 19402067)

  • 1. Sequential therapy in renal cell carcinoma.
    Escudier B; Goupil MG; Massard C; Fizazi K
    Cancer; 2009 May; 115(10 Suppl):2321-6. PubMed ID: 19402067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy in the treatment of metastatic renal cell cancer.
    Di Lorenzo G; Scagliarini S; Di Napoli M; Scognamiglio F; Rizzo M; Carteni' G
    Oncology; 2009; 77 Suppl 1():122-31. PubMed ID: 20130440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.
    Yang CH; Chuang CK; Hsieh JJ; Chang JW
    Expert Opin Drug Saf; 2010 May; 9(3):459-70. PubMed ID: 20113155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line therapy for refractory renal-cell carcinoma.
    Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
    Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
    Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?
    Rini BI; Bukowski RM
    Oncology (Williston Park); 2008 Apr; 22(4):388-96; discussion 396, 402-3, 476 passim. PubMed ID: 18472614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of metastatic renal cell carcinoma in the era of targeted therapies.
    Webber K; Cooper A; Kleiven H; Yip D; Goldstein D
    Intern Med J; 2011 Aug; 41(8):594-605. PubMed ID: 21627746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.
    Vano YA; Tartour E; Fournier LS; Beuselinck B; Mejean A; Oudard S
    Expert Rev Anticancer Ther; 2014 May; 14(5):523-42. PubMed ID: 24640949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination targeted therapy in advanced renal cell carcinoma.
    Sosman J; Puzanov I
    Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the medical treatment of metastatic renal cell carcinoma.
    Ravaud A; Wallerand H; Culine S; Bernhard JC; Fergelot P; Bensalah K; Patard JJ
    Eur Urol; 2008 Aug; 54(2):315-25. PubMed ID: 18485581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
    Rini BI; Flaherty K
    Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Kapoor A; Figlin RA
    Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Systemic therapy for metastatic renal cell carcinoma].
    Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
    Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.